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PURPOSE. CTG trinucleotide repeat (TNR) expansion is frequently found in transcription
factor 4 (TCF4) in Fuchs’ endothelial corneal dystrophy (FECD), though the effect of TNR
expansion on FECD pathophysiology remains unclear. The purpose of this study was to
evaluate the effect of TNR expansion on TCF4 expression in corneal endothelium of patients
with FECD.
METHODS. Peripheral blood DNA and Descemet membrane with corneal endothelium were
obtained from 203 German patients with FECD. The CTG TNR repeat length in TCF4 was
determined by short tandem repeat (STR) assays and Southern blotting using genomic DNA.
Genotyping of rs613872 in TCF4 was performed by PCR. TCF4 mRNA levels in corneal
endothelium were evaluated by quantitative PCR using three different probes. Control
corneal endothelial samples were obtained from 35 non-FECD subjects.
RESULTS. The STR assay and Southern blotting showed that 162 of the 203 patients with FECD
(80%) harbored CTG trinucleotide repeat lengths larger than 50. Quantitative PCR using all
three probes demonstrated that TCF4 mRNA is significantly upregulated in the corneal
endothelium of patients with FECD, regardless of the presence of TNR expansion. However,
the length of the TNR tended to show a positive correlation with TCF4 expression level. No
correlation was shown between the genotype of TCF4 SNP, rs613872, and the level of TCF4
expression.
CONCLUSIONS. Our findings showed that TCF4mRNA is upregulated in the corneal endothelium
of patients with FECD. Further studies on the effects of TCF4 upregulation on corneal
endothelial cell function will aid in understanding the pathophysiology of FECD.
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Fuchs’ endothelial corneal dystrophy (FECD) is characterizedby a loss of corneal endothelial cells that is associated with a
clinically phenotypical hallmark of guttae, which are excres-
cences of Descemet membrane formed by abnormal deposition
of extracellular matrix. As the corneal endothelium maintains
corneal transparency by regulating the degree of hydration in
the corneal stroma, severe corneal endothelial cell loss due to
FECD induces corneal haziness, resulting in vision loss.1,2
FECD is a hereditary disease with a typically autosomal
dominant pattern of inheritance, though the genetic basis is not
fully elucidated.1,2 In 2012, Wieben and colleagues3 reported
that expansion of a trinucleotide repeat (TNR) in the third
intron of TCF4 was strongly associated with FECD, and the
sensitivity and specificity for identifying FECD in their patient
cohort was 79% and 96%, respectively.3 They postulated that
FECD is a TNR disorder within the non-coding region, with
similarities to Friedreich’s ataxia, myotonic dystrophy type 1,
and fragile X syndrome.3 Subsequently, other researchers have
replicated this strong association in other independent cohorts
such as Caucasian, Indian, Chinese, and Japanese.4–9
Simple sequence repeats exist throughout the human
genome, but expansion of the TNR was discovered as causal
genetic basis in patients with spinal and bulbar muscle atrophy
in 1991.10 Since the first discovery of TNR expansion disease,
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more than 20 disorders have been identified, all of which are
neurologic or neuromuscular degenerations.11–13 TNR expan-
sion disease can be categorized into two groups: TNR
expansion disease occurring in coding regions or TNR
expansion disease occurring in noncoding regions. Diseases
with CAG repeat expansion in coding regions induce
polyglutamine tracts, which generate toxic proteins. By
contrast, TNR expansion in noncoding regions in triplet repeat
disorders can suppress or enhance gene transcription of the
surrounding gene, produce antisense RNA, alter the RNA
splicing pattern by sequestration of splicing factors, result in
intron retention, and/or have repeat-associated non-ATG (RAN)
translation, and eventually play an essential role in pathophys-
iology.13–19
Elucidation of the effect of TNR expansion on expression of
the gene harboring the expansion is beneficial for understand-
ing the pathophysiology of triplet repeat diseases; however, the
effect of TNR expansion on the transcription of TCF4 is not
well elucidated in FECD. In the current study, we collected
peripheral blood samples from 398 German patients with
FECD, as well as the Descemet membrane and associated
corneal endothelium when these patients underwent Desce-
met membrane endothelial keratoplasty (DMEK). We subse-
quently evaluated whether expression levels in the corneal
endothelium were altered by TNR expansion in TCF4 in
samples derived from 203 of these FECD subjects.
MATERIALS AND METHODS
Ethics Statement
Institutional review board approvals for research involving
human subjects were obtained from the Friedrich-Alexander
University Erlangen-Nu¨rnberg, Doshisha University, Kyoto
Prefectural University of Medicine, and the Mayo Clinic. The
human tissue was handled under the guidelines based on the
tenets of the Declaration of Helsinki. Non-FECD human donor
corneas were obtained from SightLife (Seattle, WA, USA).
Study Participants
The 398 patients with FECD who were scheduled for DMEK
were recruited between October 2013 and September 2015 at
the Department of Ophthalmology, Friedrich-Alexander Uni-
versity Erlangen-Nu¨rnberg. After informed consent, peripheral
blood samples were collected and Descemet membranes with
corneal endothelial cells (CECs) were obtained during DMEK.
For samples utilized in this study, genomic DNA obtained from
peripheral blood required a DNA concentration of ‡3.0 lg/mL
and total RNA isolated from CEC’s required an RNA integrity
number (RIN) ‡5.2. Of the samples from the 398 patients, 203
fulfilled the quality criteria for genomic DNA and total RNA
isolation. As controls, genomic DNA was isolated from donor
corneas (corneal stroma) of 35 non-FECD subjects, and cDNA
was synthesized from the CECs of the same 35 non-FECD
subjects.
Preparation of Genomic DNA From Peripheral
Blood and Donor Corneas
Genomic DNA was isolated from 200 lL of peripheral blood of
FECD subjects or non-FECD donor corneal stromas with a
commercial DNA kit (DNeasy Blood & Tissue Kit; Qiagen,
Hilden, Germany). Briefly, peripheral blood and stromas were
lysed with protease K, the lysate was applied to spin columns
(DNeasy Mini Spin Columns; Qiagen), and the columns were
washed with ethanol and then with buffer to elute the genomic
DNA. The amount and quality of each isolated DNA sample
were analyzed by UV spectrophotometry (NanoDrop; Nano-
Drop Technologies, Wilmington, DE, USA). As a control,
genomic DNA was isolated from corneal stromas of the 35
non-FECD donor corneas.
Preparation of Total RNA and Synthesis of cDNA
From Corneal Endothelium
An RNA extraction kit (RNeasy Mini Kit; Qiagen) was used to
extract total RNA from the corneal endothelium obtained from
the 203 FECD patients during DMEK. Briefly, Descemet
membranes with corneal endothelium were lysed, and the
lysate was applied to spin columns (Qiagen) with ethanol. The
total RNAwas eluted from columns, and cDNAwas synthesized
using a master mix (SuperScript VILO Master Mix; Thermo
Fisher Scientific Inc., Waltham, MA, USA). As a control,
Descemet membranes with corneal endothelium were peeled
from the 35 non-FECD donor corneas, and cDNA was
synthesized from the extracted total RNA.
Evaluation of CTG TNR Length
The CTG TNR length in TCF4 was evaluated by a short tandem
repeat (STR) assay, as described previously.4 Briefly, PCR was
performed for the CTG repeat region using one fluorescently
labeled primer. The size of the products was determined by
capillary electrophoresis on a DNA analyzer (ABI 3730xl;
Applied Biosystems, Foster City, CA). Samples that showed a
single signal by STR were further analyzed by Southern blotting
(described previously)3 using unamplified genomic DNA to
determine if these samples carried a large repeat.
Quantitative Real-Time PCR
Quantitative real-time PCR (qPCR) was performed with a real-
time PCR system (QuantStudio 3; Applied Biosystems). All
samples were analyzed in duplicate with a program of 958C for
20 seconds and 40 cycles of 958C for 1 second and 608C for 20
seconds. For quantification, standard curves were run in
parallel using serial dilutions (5-55copies) of cDNA of cultured
immortalized human CECs, as described previously.20 Ratios
relative to GAPDH were calculated for normalization of gene
expression levels. In this study, qPCR was based on a hydrolysis
probe system (TaqMan; Thermo Fisher Scientific, Inc.). The
hydrolysis probes (Thermo Fisher Scientific, Inc.) were for
TCF4, Hs 00971338_m1; Hs00162613_m1; Hs00972432_m1;
and predevelopment human GAPDH (Thermo Fisher Scientif-
ic, Inc.).
Genotyping
Genotyping of rs613872 in TCF4 was performed by PCR using
the following primers: forward primer-50-actgtcaagcactaagcaaa
gagg-30, reverse primer- 50-cccagtagggttgtgatgatgatg-3 0. PCR
reactions were carried out with Ex Taq DNA polymerase
(Takara Bio Inc., Otsu, Japan) under the following conditions: 1
cycle of denaturation at 948C for 2 minutes followed by 35
cycles of denaturation at 948C for 30 seconds, annealing at
558C for 30 seconds, and elongation at 728C for 30 seconds.
Upon completion of the 35 cycles, a final elongation was
performed at 728C for 5 minutes. The PCR products were
separated by electrophoresis on 2% agarose gels in Tris-acetate
buffer, stained with ethidium bromide, imaged with a
luminescence imager (LAS4000S; Fuji Film, Tokyo, Japan),
and then extracted from the agarose gels using the a
commercial gel and a PCR cleanup system (Wizard SV Gel;
Promega, Madison, WI, USA). A terminator cycle sequencing
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kit and a DNA sequencer (Taq DyeDeoxy and 373A DNA
sequencer; Applied Biosystems) were used for direct sequenc-
ing.
Statistical Analysis
Statistical analysis was performed with the R version 3.4.3 (R
Foundation for Statistical Computing, Vienna, Austria). Possible
confounding effects of sex and age of the subjects were
assessed using the correlations between the case and control
samples with the Student’s t test or the Fisher exact test.
Wilcoxon rank sum test was used to detect difference of
expression of TCF4 level between sexes. The statistical
significance for the comparison of multiple sample sets was
determined with the Steel-Dwass test. Spearman’s rank
correlation coefficient was used to determine any significant
correlations between the CTG repeat length and expression of
TCF4 mRNA level. Results are expressed as mean 6 SD.
Statistical significance was defined as P value < 0.05.
RESULTS
TNR Expansion in Patients With FECD
We first determined the lengths of the CTG TNR expansions in
TCF4 by analyzing genomic DNA from peripheral blood
samples of 203 patients with FECD and from control corneal
stromas from 35 non-FECD subjects. The STR assays and
Southern blotting demonstrated that all 35 non-FECD control
subjects had CTG TNR lengths <50, whereas 162 of 203
patients with FECD (80%) harbored CTG TNR lengths ‡50.
The remaining 41 patients with FECD (20%) had TNR lengths
<50 (Table). The mean subject age was 58.0 6 13.3 (range, 21
to 92) years in the control group, 68.9 6 10.3 (range, 42 to 90)
in the FECD group without TNR expansion, and 69.8 6 9.4
(range, 34 to 87) in the FECD group with TNR expansion.
Consistent with previous reports,2 the female ratio was higher
in the FECD subjects (11 males and 30 females with CTG < 50,
and 74 males and 88 females with CTG ‡ 50).
Expression Levels of TCF4 in the Corneal
Endothelium of Patients With FECD
We used qPCR to evaluate the expression level of TCF4 in the
corneal endothelium of patients with FECD. As TCF4 has
multiple alternatively spliced isoforms, we used three probes
(Thermo Fisher Scientific, Inc.) for qPCR that are all contained
within the canonical TCF4 transcript (Refseq: NM_001083962)
that encodes TCF4-B (Fig. 1). The expression level of TCF4
determined by Hs00971338 was significantly higher in patients
with FECD with or without CTG TNR expansion >50 than in
non-FECD subjects (control: 7.2 6 4.8; FECD without
expansion: 22.3 6 29.9; and FECD without expansion: 47.4
6 46.3; P < 0.01). The TCF4 level was also significantly
higher in FECD with expansion than in FECD without
expansion (P < 0.01; Fig. 2A). The expression level of TCF4
determined by Hs00162613 was significantly higher in patients
with FECD with or without CTG TNR expansion >50 than in
non-FECD subjects (control: 2.2 6 1.3, FECD without
expansion: 4.5 6 1.6, and FECD without expansion: 4.3 6
1.3; P < 0.01); however, no statistically significant difference
was observed in TCF4 levels between FECD with expansion
and FECD without expansion (Fig. 2B). The expression level of
TCF4 determined by Hs00972432 was higher in FECD with or
without CTG TNR expansion >50 than in non-FECD subjects
(control: 2.8 6 3.1, FECD without expansion: 6.7 6 4.9, and
FECD without expansion: 10.8 6 8.2), but only the TCF4 level
in FECD with expansion showed statistical significance when
compared with the control subjects (P < 0.01). Consistent
with the TCF4 level determined by Hs00971338, the TCF4
level determined by Hs00972432 was significantly higher in
FECD with expansion than in FECD without expansion (P <
0.01; Fig. 2C).
Effect of CTG Repeat Length or Genotype on TCF4
Expression Level
We evaluated whether the CTG TNR length or the genotype of
the single nucleotide polymorphism (SNP) rs613872 in TCF4
correlated with TCF4 expression levels in FECD. Spearman’s
correlation coefficient by rank test revealed a weak positive
correlation between CTG TNR length in genomic DNA from
peripheral blood and the expression level of TCF4 in the
corneal endothelium determined by Hs00971338 (q ¼ 0.24, P
< 0.01) and Hs00972432 (q ¼ 0.22, P < 0.01; Figs. 3A, 3C).
Conversely, the CTG TNR length did not show significant
correlation with expression level of TCF4 determined by
Hs00162613 (Fig. 3B). We also evaluated the effect of other
potent confounders, including sex and age, on the expression
level of TCF4. The expression level of TCF4 (normalized by
expression level of GAPDH) in the corneal endothelium,
determined by Hs00971338, was 39.1 6 49.7 in males and
TABLE. Demographic Data of Patients With FECD and non-FECD
Controls
CTG Repeat
P Value
Control
No Expansion Expansion
CTG < 50 CTG ‡ 50
(n ¼ 35) (n ¼ 41) (n ¼ 162)
Age, y 58.0 6 13.1
(21, 92)
68.9 6 10.2
(42, 90)
69.8 6 9.4
(34, 87)
<0.01*
Sex <0.01†
Male 28 11 74
Female 7 30 88
Data represent the mean 6 SD (minimum, maximum).
* P value of Student’s t-test for case and control age comparisons.
† P value of Fisher exact test for case and control sex comparisons.
FIGURE 1. Schematic image of TCF4 and the genomic regions recognized by hydrolysis probes. Hs00971338 recognized the N-terminal side of
active domain 1 (AD1), Hs00162613 recognized the N-terminal side of active domain 2 (AD2), and Hs00972432 recognized the N-terminal side of
basic helix-loop-helix (bHLH) of TCF4.
TCF4 Expression in Fuchs’ Endothelial Corneal Dystrophy IOVS j February 2019 j Vol. 60 j No. 2 j 781
Downloaded from arvojournals.org on 03/01/2019
35.4 6 36.2 in females (P¼0.77). Likewise, expression level of
TCF4 was similar level between sexes, at 3.9 6 1.6 in males
and 4.1 6 1.4 in females, determined by Hs00162613 (P ¼
0.29), and 8.1 6 6.7 in males and 9.7 6 8.6 in females (P ¼
0.10), determined by Hs00972432. Since Wirgenes and
colleagues previously reported that age showed a very weak
positive correlation with TCF4mRNA levels in blood,21 we also
evaluated the correlation between age and the expression level
of TCF4 in the corneal endothelium. Spearman’s correlation
coefficient by rank test did not show a significant correlation
with the expression level of TCF4, determined by Hs00162613
and Hs00972432, though the expression level determined by
Hs00971338 revealed a weak positive correlation with
marginal statistical significance (Supplementary Fig. S1).
Consistent with previous reports confirming the ‘‘G’’ risk
allele in rs613872,22 genotyping results showed that the
genotype of this TCF4 SNP was TT:30 (15%), TG:140 (69%),
and GG:33 (16%) in German FECD cases, while it was TT:27
(77%), TG:7 (20%), and GG:1 (3%) in the control subjects (P <
0.01). No correlation was found between the genotype of TCF4
FIGURE 2. Expression of TCF4 mRNA in corneal endothelium of patients with FECD. (A) Total RNA was extracted from the corneal endothelium of
the 203 patients with FECD and 35 non-FECD subjects, and cDNA was synthesized. The expression level of TCF4 determined by Hs00971338 was
significantly higher in FECD with or without a CTG expansion of a trinucleotide repeat (TNR) expansion larger than 50 when compared with non-
FECD subjects. In addition, TCF4 level was significantly higher in FECD with expansion than in FECD without expansion. * P < 0.01. (B) Expression
level of TCF4 determined by Hs00162613 was significantly higher in FECD with or without a CTG TNR expansion larger than 50 than in non-FECD
subjects. *P < 0.01. (C) Expression level of TCF4 determined by Hs00972432 was higher in FECD with or without CTG-TNR expansion larger than
50 when compared to non-FECD subjects, but TCF4 level showed a statistically significant difference only in FECD with expansion when compared
to the control subjects. The TCF4 level determined by Hs00972432 was significantly higher in FECD with expansion than in FECD without
expansion. *P < 0.01. The statistical significance was determined with the Steel-Dwass test.
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SNP rs613872 and expression level of TCF4 determined by all
three probes (Figs. 4A–C).
DISCUSSION
Diseases with TNR expansion in non-coding regions typically
cause a loss of gene function or toxic effects at the mRNA level,
but their pathophysiology varies depending on the type and
the location of the TNR.12,13 For example, myotonic dystrophy
1 harbors CTG repeats within the 30 UTR in the myotonic
dystrophy protein kinase (DMPK) gene. These CTG repeats in
DMPK gene lead to the formation of transcript aggregates in
the nucleus (referred to as RNA foci) that sequester RNA-
binding proteins, resulting in a spliceopathy of downstream
effector genes.23 In Friedreich’s ataxia, a GAA repeat expansion
in the first intron of the frataxin gene suppresses the frataxin
mRNA and protein expression, leading to impaired mitochon-
drial iron transport.24–26 Likewise, a CGG repeat expansion in
the 50UTR of the fragile X mental retardation gene (FMR1)27
represses transcription by CpG hypermethylation of the FMR1
promoter.28 However, suppression of gene expression by
repeats is not always identified among triplet repeat expansion
diseases. In spinocerebellar ataxia type 12, overexpression of
the PPP2R2B gene29 is linked to the length of a CAG TNR
expansion, suggesting this is involved in the underlying
pathophysiology.30 These reports encouraged us to conduct
the current study to answer the simple but fundamental
question: ‘‘Does CTG repeat expansion in FECD alter the
expression of TCF4 mRNA level in the corneal endothelium?’’
Studies reporting the expression of TCF4 in patients with
FECD have resulted in contrasting conclusions. For example,
Mootha and colleagues31 reported no alterations in TCF4 levels
in the corneal endothelium of FECD patients when compared
to control subjects. Likewise, Oldak and colleagues32 analyzed
the corneal endothelium from 40 FECD cases and 23 control
subjects, and showed similar expression levels of TCF4 in both
groups and stable TCF4 levels regardless of the risk allele of
rs613872. By contrast, Foja and colleagues9 reported decreased
TCF4 levels in the corneal endothelium of FECD patients in
their examination of 6 FECD patients with TNR expansion >50
and 5 controls with TNR expansion <50.
In the current study, we demonstrated a significantly higher
expression of TCF4 at the mRNA level in the corneal
endothelium of patients with FECD compared to normal
FIGURE 3. Correlation between CTG-TNR length and expression of TCF4mRNA. (A) CTG TNR length was evaluated by analyzing the genomic DNA
from peripheral blood and expression levels were plotted for TCF4mRNA in the corneal endothelium of patients with FECD. Spearman’s correlation
coefficient by rank test revealed a weak positive correlation between CTG-TNR length and expression level of TCF4 determined by Hs00971338 (q
¼ 0.24, P < 0.01). (B) CTG-TNR length did not show a significant correlation with the expression level of TCF4 determined by Hs00162613 (q¼
0.01, P¼0.884). (C) CTG-TNR length showed a weak positive correlation with the expression level of TCF4 determined by Hs00972432 (q¼0.22, P
< 0.01). Correlation was determined by a rank test using Spearman’s correlation coefficient.
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controls. However, TCF4 has multiple alternatively spliced
variants and the variants expressed in corneal endothelium
have not been elucidated. Therefore, we examined the splicing
variants of TCF4 at three different loci that correlated with
conserved motifs in the TCF4 protein sequence, and we found
upregulation of TCF4 transcription in the patients with FECD,
even in the patients without TNR expansion. Interestingly, the
CTG repeat length, but not the presence of risk allele G in
rs613872, tended to correlate with the TCF4 mRNA level.
Further studies will be necessary to address whether expan-
sion upregulates TCF4 transcription and if the increase in TCF4
transcription has toxic effects in the corneal endothelium.
TCF4 encodes numerous transcripts, but the probeset
Hs00971338, located proximally (50) to the TNR, will only
amplify the canonical TCF4 transcript encoding TCF4-B.
Interestingly, the qPCR results showed that levels of the
TCF4-B transcript are significantly elevated in FECD cases with
repeat expansions when compared to cases without an
expansion and controls. This finding may indicate a differential
effect of the FECD-associated TNR in TCF4 on the expression
of the different TCF4 transcripts in CECs.
TCF4 is a basic helix-loop-helix (bHLH) transcription factor
that plays an important role in various developmental
processes.33 One large-scale genome-wide association study
(GWAS) identified TCF4 as the first gene to show a strong
association with schizophrenia.34 TCF4 variants have also
shown associations with primary sclerosing cholangitis and
Pitt-Hopkins syndrome, as well as with FECD.33 The role of
TCF4 in the context of disease pathogenesis still remains
unclear, but involvement in the regulation of the epithelial-
mesenchymal transition (EMT) was described in certain cell
types. For instance, the overexpression of TCF4 in kidney cells
induced EMT by upregulation of EMT-related markers.35 In
human neuroblastoma cells, genome-wide expression profiling
showed that knockdown of TCF4 altered multiple signaling
pathways related to the EMT and to transforming growth
factor-b (TGF-b), an essential mediator of the EMT.36 We
established a cell model from patients with FECD and showed
that TGF-b upregulates EMT-related genes, thereby inducing
FIGURE 4. Correlation between the genotype of TCF4 SNP, rs613872, and TCF4 expression level. Genotyping of rs613872 in TCF4 was performed
by PCR. No statistically significant correlation was revealed by the Steel-Dwass test between the genotype of TCF4 SNP rs613872 and the expression
level of TCF4 determined by three probes: (A) Hs00971338, (B) Hs001612613, and (C) Hs00972432.
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excessive extracellular matrix (ECM) protein production,
which is a hallmark of FECD.20 More recently, we reported
that upregulation of TGF-b signaling in FECD induces a chronic
overload of ECM proteins to the endoplasmic reticulum in an
immortalized cell model of FECD.37,38 The overload of ECM
protein results in accumulation of unfolded protein and
triggers the intrinsic apoptotic pathway through the unfolded
protein response.37 These findings suggested that upregulation
of TCF4 can be linked to the underlying pathology of FECD,
including upregulation of TGF-b signaling and chronic
overloading of ECM proteins in the endoplasmic reticulum.
In conclusion, we have demonstrated that TCF4 mRNA is
upregulated in patients with FECD, regardless of the presence
or absence of TNR expansion, but the length of the TNR in
cases with expansion tended to correlate with the TCF4
expression level. These findings suggest the possibility that
upregulation of TCF4 plays a central role in FECD. However,
further studies are needed to identify the ‘‘missing link’’
between the increases in TCF4 mRNA and the proposed
pathophysiology that appears to involve upregulation of TGF-b
signaling, disruption of protein loading in the endoplasmic
reticulum.
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